| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/ANNRHEUMDIS-2012-202442 |
| P698 | PubMed publication ID | 23482473 |
| P50 | author | Iain McInnes | Q41687181 |
| M Julia Brosnan | Q114778704 | ||
| P2093 | author name string | Zhen Luo | |
| Ho-Youn Kim | |||
| Yeong-Wook Song | |||
| Sang-Heon Lee | |||
| Andrea Zuckerman | |||
| Samuel H Zwillich | |||
| John D Bradley | |||
| David Mandel | |||
| Carol A Connell | |||
| P2860 | cites work | Janus kinases in immune cell signaling | Q24322021 |
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Cytokines in the pathogenesis of rheumatoid arthritis | Q28303865 | ||
| The pathogenesis of rheumatoid arthritis | Q29614957 | ||
| Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). | Q34169114 | ||
| Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 | ||
| Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 | ||
| Current and novel therapeutics in the treatment of systemic lupus erythematosus | Q34648851 | ||
| The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Q34989826 | ||
| Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis | Q36098818 | ||
| Statins accelerate the onset of collagen type II-induced arthritis in mice | Q36245870 | ||
| New therapies for treatment of rheumatoid arthritis | Q36849874 | ||
| Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions | Q37415092 | ||
| Treatment of rheumatoid arthritis: state of the art 2009. | Q37607063 | ||
| Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives | Q37812524 | ||
| Mechanisms for the anti-inflammatory effects of statins | Q37853818 | ||
| Particle size: the key to the atherogenic lipoprotein? | Q40595133 | ||
| 'Rac'-ing upstream to treat rheumatoid arthritis | Q42682417 | ||
| Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis | Q58912330 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 124-131 | |
| P577 | publication date | 2013-03-12 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study | |
| P478 | volume | 73 |
| Q91776881 | Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions |
| Q34563216 | Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment |
| Q92184778 | Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies |
| Q54172510 | Chemical JAK inhibitors for the treatment of rheumatoid arthritis. |
| Q64102958 | Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis |
| Q42394345 | Decernotinib: A Next-Generation Jakinib |
| Q26851763 | Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis |
| Q50107707 | Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis |
| Q38745362 | Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis |
| Q26748085 | Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist |
| Q92546940 | Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data |
| Q35054330 | Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies |
| Q38689012 | Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials |
| Q37316891 | Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial |
| Q41912068 | Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy |
| Q34851473 | Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis |
| Q50214328 | Immune modulatory effects of statins. |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q24202363 | Lipid lowering efficacy of atorvastatin |
| Q49792187 | Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies |
| Q24187301 | Lipid-lowering efficacy of atorvastatin |
| Q31158500 | Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. |
| Q41931494 | Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program |
| Q39210337 | Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches |
| Q92771536 | Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis |
| Q93072607 | Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases |
| Q38236740 | Rheumatoid arthritis and metabolic syndrome |
| Q38411930 | Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists |
| Q26784397 | Systemic Review and Meta-Analysis of the Clinical Efficacy and Adverse Effects of Zhengqing Fengtongning Combined with Methotrexate in Rheumatoid Arthritis |
| Q50109832 | The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review |
| Q50192090 | The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis |
| Q92544807 | The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors |
| Q54978346 | Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety. |
| Q90243664 | Tofacitinib in the treatment of active rheumatoid arthritis - single-centre experience |
| Q36859619 | Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme |
| Q43280727 | Tofacitinib: A Review in Rheumatoid Arthritis |
| Q38110227 | Tofacitinib: a review of its use in adult patients with rheumatoid arthritis |
| Q36968737 | Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis |
| Q34030650 | Update on Janus kinase antagonists in inflammatory bowel disease |
Search more.